Myelofibrosis, JAK2 inhibitors and erythropoiesis
نویسندگان
چکیده
منابع مشابه
Intrinsic resistance to JAK2 inhibition in myelofibrosis.
PURPOSE Recent results have shown that myeloproliferative neoplasms (MPN) are strongly associated with constitutive activation of the Janus-activated kinase (JAK)2 tyrosine kinase. However, JAK2 inhibitors currently approved or under development for treating myeloproliferative neoplasms do not selectively deplete the malignant clone, and the inhibition of activity of the drug target (JAK2) has ...
متن کاملExpression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo.
Activation of JAK2 by chromosomal translocation or point mutation is a recurrent event in hematopoietic malignancies, including acute leukemias and myeloproliferative disorders. Although the effects of activated JAK2 signaling have been examined in cell lines and murine models, the functional consequences of deregulated JAK2 in the context of human hematopoietic cells are currently unknown. Her...
متن کاملJAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis.
OBJECTIVE JAK2 V617F, MPL W515L and JAK2 exon 12 mutations are novel acquired mutations that induce constitutive cytokine-independent activation of the JAK-STAT pathway in myeloproliferative disorders (MPD). The discovery of these mutations provides novel mechanism for activation of signal transduction in hematopoietic malignancies. This research was to investigate their prevalence in Chinese p...
متن کاملFolic-acid Deficiency and Megaloblastic Erythropoiesis in Myelofibrosis.
Folic-acid deficiency may arise in conditions which produce an increased demand for the vitamin. Diseases in this category include acute leukaemia, disseminated carcinomatosis (Girdwood, 1959), myelofibrosis (Chanarin, Mollin, and Anderson, 1958), and haemolytic anaemia (Chanarin, Dacie, and Mollin, 1959). The presence of megaloblastic erythropoiesis in myelofibrosis has been described in only ...
متن کاملJAK inhibitors and myelofibrosis, Einstein and ruxolitinib.
This year marks a decade since the original descriptions of the JAK2 mutation in myeloproliferative neoplasms. 4 In the intervening years we have witnessed this finding influencing diagnostic processes, prognostic determination and more recently therapeutics. Whilst some perhaps naively anticipated that the benefits of JAK2 as a therapeutic target would parallel those of BCR/ABL inhibitors we h...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2013
ISSN: 0887-6924,1476-5551
DOI: 10.1038/leu.2013.72